The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold)., and Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Approaching treatment decisions in newly diagnosed BPDCN
In this video, Andrew Lane, MD, PhD, Dana Farber Cancer Institute, Boston, MA, discusses the approach to treating blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the newly diagnosed setting, noting that for eligible patients, the goal is to achieve complete remission and proceed to stem cell transplantation (alloSCT). Dr Lane highlights that for older patients for whom SCT is not feasible, the focus is on disease control. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So for all patients with BPDCN, if they are eligible based on age and other comorbidities, we try to get them to an allogeneic stem cell transplant. There’s a subset of patients who you can’t go to an allotransplant where we also think about an autologous transplant. And so for all patients that come to us, unless they’re completely ineligible by age, our goal is to get the disease into a complete remission and go to transplant...
So for all patients with BPDCN, if they are eligible based on age and other comorbidities, we try to get them to an allogeneic stem cell transplant. There’s a subset of patients who you can’t go to an allotransplant where we also think about an autologous transplant. And so for all patients that come to us, unless they’re completely ineligible by age, our goal is to get the disease into a complete remission and go to transplant. There are those older patients. We have patients in their 80s with BPDCN who can be treated with these regimens tagraxofusp, the approved regimen, or other chemotherapy drugs. And so for those patients, the goal is control as long as possible. But again, for most patients, we are trying to get them to that transplant as soon as they get to a CR.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
